Geron (GERN) Stock Forecast & Price Target
Geron (GERN) Analyst Ratings
Bulls say
Geron Corp's recent approval of Rytelo (imetelstat) in the European Union for treating low-risk myelodysplastic syndrome (LR-MDS) is expected to enhance potential revenue streams starting in 2026, aligning with previous expectations. The company maintains a strategic focus on educating healthcare providers to drive the therapy's sales, which could significantly diversify revenue beyond previous sales dominated by third-line therapies. Additionally, the confidence expressed by the board and leadership in the therapeutic potential of imetelstat, particularly its demonstrated effectiveness in disease modification for LR-MDS, reinforces a positive outlook for Geron's long-term financial performance.
Bears say
The financial outlook for Geron Corp is notably negative due to a trend of flat revenues that may persist for an extended period, delaying any potential recovery or growth. Additionally, the postponement of pivotal IMpactMF trial results to the second half of 2026 signifies a lack of near-term value-creating events, further contributing to investor concerns. Key risks, including safety signals from clinical programs, lower-than-expected efficacy, increased competition, regulatory hurdles, and potential failures in intellectual property protection, compound the uncertainties surrounding the company's future performance.
This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.
Geron (GERN) Analyst Forecast & Price Prediction
Start investing in Geron (GERN)
Order type
Buy in
Order amount
Est. shares
0 shares